Steve N Caritis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3433970/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fetal Tachycardia in the Setting of Maternal Intrapartum Fever and Perinatal Morbidity. American Journal of Perinatology, 2024, 41, 160-166.	1.4	0
2	Racial and Ethnic Disparities in Adverse Perinatal Outcomes at Term. American Journal of Perinatology, 2023, 40, 557-566.	1.4	5
3	Antenatal Corticosteroids and Preterm Neonatal Morbidity and Mortality among Women with and without Diabetes in Pregnancy. American Journal of Perinatology, 2022, 39, 067-074.	1.4	8
4	Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy. British Journal of Clinical Pharmacology, 2022, 88, 271-281.	2.4	10
5	Association between Hypertensive Disorders of Pregnancy and Long-Term Neurodevelopmental Outcomes in the Offspring. American Journal of Perinatology, 2022, 39, 0921-0929.	1.4	4
6	An evaluation of seasonal maternal/neonatal morbidity related to trainee cycles. American Journal of Obstetrics & Gynecology MFM, 2022, , 100583.	2.6	0
7	PREDICITION OF CEREBRAL PALSY OR DEATH AMONG PRETERM INFANTS WHO SURVIVE THE NEONATAL PERIOD. American Journal of Perinatology, 2022, , .	1.4	2
8	Predictive performance of newborn small for gestational age by a United States intrauterine vs birthweight-derived standard for short-term neonatal morbidity and mortality. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100599.	2.6	0
9	Treatment of Gestational Diabetes Mellitus and Offspring Early Childhood Growth. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1849-e1858.	3.6	2
10	Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet, The, 2021, 397, 1183-1194.	13.7	110
11	Differences in obstetrical care and outcomes associated with the proportion of the obstetrician's shift completed. American Journal of Obstetrics and Gynecology, 2021, 225, 430.e1-430.e11.	1.3	Ο
12	A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. American Journal of Obstetrics and Gynecology, 2021, 225, 666.e1-666.e15.	1.3	47
13	Obstetrical, fetal, and lactation pharmacology—a crisis that can no longer be ignored. American Journal of Obstetrics and Gynecology, 2021, 225, 10-20.	1.3	20
14	Cervical length distribution and other sonographic ancillary findings of singleton nulliparous patients at midgestation. American Journal of Obstetrics and Gynecology, 2021, 225, 181.e1-181.e11.	1.3	3
15	Intrapartum Fetal Electrocardiogram in Small- and Large-for-Gestational Age Fetuses. American Journal of Perinatology, 2021, 38, 1465-1471.	1.4	0
16	Outcomes in Twins Compared With Singletons Subsequent to Preterm Prelabor Rupture of Membranes. Obstetrics and Gynecology, 2021, 138, 725-731.	2.4	1
17	Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. Frontiers in Pediatrics, 2021, 9, 733823.	1.9	17
18	A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production. American Journal of Perinatology, 2021, , .	1.4	0

#	Article	IF	CITATIONS
19	Sex-Specific Genetic Susceptibility to Adverse Neurodevelopmental Outcome in Offspring of Pregnancies at Risk of Early Preterm Delivery. American Journal of Perinatology, 2020, 37, 281-290.	1.4	3
20	Duration of Operative Vaginal Delivery and Adverse Obstetric Outcomes. American Journal of Perinatology, 2020, 37, 503-510.	1.4	8
21	Pharmacokinetics and Pharmacodynamics. , 2020, , 581-587.e1.		Ο
22	Naltrexone use in pregnancy: a time for change. American Journal of Obstetrics and Gynecology, 2020, 222, 1-2.	1.3	18
23	Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. Clinical Pharmacology and Therapeutics, 2020, 107, 1362-1372.	4.7	8
24	Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. International Journal of Epidemiology, 2020, 49, 648-656.	1.9	21
25	Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2020, 60, 540-549.	2.0	4
26	Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations. Journal of Clinical Pharmacology, 2020, 60, 477-488.	2.0	8
27	Modelâ€Informed Dose Optimization in Pregnancy. Journal of Clinical Pharmacology, 2020, 60, S63-S76.	2.0	10
28	Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. Therapeutic Drug Monitoring, 2020, 42, 264-270.	2.0	26
29	Neonatal and Maternal Composite Adverse Outcomes Among Low-Risk Nulliparous Women Compared With Multiparous Women at 39–41 Weeks of Gestation. Obstetrics and Gynecology, 2020, 136, 450-457.	2.4	13
30	Effects of Pregnancy on the Pharmacokinetics of Metformin. Drug Metabolism and Disposition, 2020, 48, 264-271.	3.3	31
31	Association Between Time of Day and the Decision for an Intrapartum Cesarean Delivery. Obstetrics and Gynecology, 2020, 135, 535-541.	2.4	3
32	Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation. American Journal of Perinatology, 2020, , .	1.4	1
33	A Model to Predict Vaginal Delivery and Maternal and Neonatal Morbidity in Low-Risk Nulliparous Patients at Term. American Journal of Perinatology, 2020, , .	1.4	Ο
34	Opioids affect the fetal brain: reframing the detoxification debate. American Journal of Obstetrics and Gynecology, 2019, 221, 602-608.	1.3	32
35	Cost-effectiveness of Antenatal Corticosteroid Therapy vs No Therapy in Women at Risk of Late Preterm Delivery. JAMA Pediatrics, 2019, 173, 462.	6.2	25
36	Cord Blood Haptoglobin, Cerebral Palsy and Death in Infants of Women at Risk for Preterm Birth: A Secondary Analysis of a Randomised Controlled Trial. EClinicalMedicine, 2019, 9, 11-18.	7.1	4

#	Article	IF	CITATIONS
37	Reply. American Journal of Obstetrics and Gynecology, 2019, 220, 608-609.	1.3	Ο
38	Association of Labor With Neonatal Respiratory Outcomes at 36–40 Weeks of Gestation. Obstetrics and Gynecology, 2019, 134, 495-501.	2.4	3
39	In Reply. Obstetrics and Gynecology, 2019, 133, 190-191.	2.4	0
40	Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 83-89.	1.6	5
41	Response to Medical Nutritional Therapy and Need for Pharmacological Therapy in Women with Gestational Diabetes. American Journal of Perinatology, 2019, 36, 1250-1255.	1.4	2
42	Daytime Compared With Nighttime Differences in Management and Outcomes of Postpartum Hemorrhage. Obstetrics and Gynecology, 2019, 133, 155-162.	2.4	5
43	The Role of Preterm Birth in the Association Between Opioid Maintenance Therapy and Neonatal Abstinence Syndrome. Paediatric and Perinatal Epidemiology, 2018, 32, 213-222.	1.7	23
44	Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate. American Journal of Perinatology, 2018, 35, 809-814.	1.4	4
45	Pregnancy outcomes in women with an early diagnosis of gestational diabetes mellitus. Diabetes Research and Clinical Practice, 2018, 138, 177-186.	2.8	33
46	Defining failed induction of labor. American Journal of Obstetrics and Gynecology, 2018, 218, 122.e1-122.e8.	1.3	75
47	Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth. American Journal of Perinatology, 2018, 35, 1012-1022.	1.4	11
48	Evaluation of 17-alpha hydroxyprogesterone caproateÂefficacy. American Journal of Obstetrics and Gynecology, 2018, 218, 261.	1.3	2
49	The Association of Decision-to-Incision Time for Cesarean Delivery with Maternal and Neonatal Outcomes. American Journal of Perinatology, 2018, 35, 247-253.	1.4	13
50	Impact of Pregnancy History and 17-Hydroxyprogesterone Caproate on Cervical Cytokines and Matrix Metalloproteinases. American Journal of Perinatology, 2018, 35, 470-480.	1.4	3
51	Association Between Gestational Weight Gain and Perinatal Outcomes. Obstetrics and Gynecology, 2018, 132, 875-881.	2.4	80
52	Maternal Outcomes Associated With Lower Range Stage 1 Hypertension. Obstetrics and Gynecology, 2018, 132, 843-849.	2.4	84
53	Defining the clinical response to 17-alpha hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2018, 219, 623-625.	1.3	3
54	Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort. Hypertension, 2018, 72, 202-207.	2.7	50

#	Article	IF	CITATIONS
55	Neonatal outcomes of elective early-term births after demonstrated fetal lung maturity. American Journal of Obstetrics and Gynecology, 2018, 219, 296.e1-296.e8.	1.3	21
56	Variation in the Nulliparous, Term, Singleton, Vertex Cesarean Delivery Rate. Obstetrics and Gynecology, 2018, 131, 1039-1048.	2.4	19
57	Prednisone Pharmacokinetics During Pregnancy and Lactation. Journal of Clinical Pharmacology, 2018, 58, 1223-1232.	2.0	29
58	Gestational changes in buprenorphine exposure: A physiologicallyâ€based pharmacokinetic analysis. British Journal of Clinical Pharmacology, 2018, 84, 2075-2087.	2.4	26
59	Nausea and vomiting of pregnancy - What's new?. Autonomic Neuroscience: Basic and Clinical, 2017, 202, 62-72.	2.8	86
60	Neonatal outcomes following preterm birth classified according to placental features. American Journal of Obstetrics and Gynecology, 2017, 216, 411.e1-411.e14.	1.3	87
61	Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. New England Journal of Medicine, 2017, 376, 815-825.	27.0	363
62	The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2017, 217, 369.e1-369.e9.	1.3	9
63	Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. JAMA - Journal of the American Medical Association, 2017, 317, 1047.	7.4	142
64	Delayed villous maturation in term placentas exposed to opioid maintenance therapy: a retrospective cohort study. American Journal of Obstetrics and Gynecology, 2017, 216, 418.e1-418.e5.	1.3	26
65	Glycemic Control and Pregnancy Outcomes in Women with Type 2 Diabetes Treated with Oral Hypoglycemic Agents. American Journal of Perinatology, 2017, 34, 697-704.	1.4	3
66	Predictive Characteristics of Elevated 1-Hour Glucose Challenge Test Results for Gestational Diabetes. American Journal of Perinatology, 2017, 34, 1464-1469.	1.4	1
67	A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. British Journal of Clinical Pharmacology, 2017, 83, 2458-2473.	2.4	23
68	Role of early second-trimester uterine artery Doppler screening to predict small-for-gestational-age babies in nulliparous women. American Journal of Obstetrics and Gynecology, 2017, 217, 594.e1-594.e10.	1.3	45
69	Neonatal Morbidity of Small- and Large-for-Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies. Obstetrics and Gynecology, 2017, 130, 511-519.	2.4	101
70	Racial and Ethnic Differences in Utilization of Labor Management Strategies Intended to Reduce Cesarean Delivery Rates. Obstetrics and Gynecology, 2017, 130, 1285-1294.	2.4	47
71	An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. American Journal of Obstetrics and Gynecology, 2017, 217, 459.e1-459.e6.	1.3	41
72	Placental maternal vascular malperfusion and adverse pregnancy outcomes in gestational diabetes mellitus. Placenta, 2017, 49, 10-15.	1.5	60

#	Article	IF	CITATIONS
73	Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy. American Journal of Obstetrics and Gynecology, 2017, 216, 64.e1-64.e7.	1.3	46
74	Association of Cervical Effacement With the Rate of Cervical Change in Labor Among Nulliparous Women. Obstetrics and Gynecology, 2016, 127, 489-495.	2.4	6
75	Carpenter-Coustan Compared With National Diabetes Data Group Criteria for Diagnosing Gestational Diabetes. Obstetrics and Gynecology, 2016, 127, 893-898.	2.4	36
76	Population pharmacokinetics of 17αâ€hydroxyprogesterone caproate in singleton gestation. British Journal of Clinical Pharmacology, 2016, 82, 1084-1093.	2.4	12
77	Association of the Duration of Active Pushing With Obstetric Outcomes. Obstetrics and Gynecology, 2016, 127, 667-673.	2.4	73
78	Evaluation of delivery options for second-stage events. American Journal of Obstetrics and Gynecology, 2016, 214, 638.e1-638.e10.	1.3	60
79	What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth. Seminars in Perinatology, 2016, 40, 273-280.	2.5	7
80	Effectiveness of doxylamine-pyridoxine for morning sickness. American Journal of Obstetrics and Gynecology, 2016, 214, 664-666.	1.3	7
81	Racial/Ethnic Disparities in Measures of Self-reported Psychosocial States and Traits during Pregnancy. American Journal of Perinatology, 2016, 33, 1426-1432.	1.4	43
82	Ondansetron Exposure Changes in a Pregnant Woman. Pharmacotherapy, 2016, 36, e139-e141.	2.6	14
83	Polymorphisms in <i>CYP1A1</i> and <i>CYP3A5</i> Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting. Pharmacotherapy, 2016, 36, 1238-1244.	2.6	6
84	Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy. BMC Pregnancy and Childbirth, 2016, 16, 371.	2.4	5
85	Maternal and Neonatal Outcomes With Early Compared With Delayed Pushing Among Nulliparous Women. Obstetrics and Gynecology, 2016, 128, 1039-1047.	2.4	20
86	Prediction of Spontaneous Preterm Birth Among Nulliparous Women With a Short Cervix. Journal of Ultrasound in Medicine, 2016, 35, 1293-1297.	1.7	21
87	Pharmacokinetics of metoprolol during pregnancy and lactation. Journal of Clinical Pharmacology, 2016, 56, 581-589.	2.0	52
88	Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy. American Journal of Obstetrics and Gynecology, 2016, 215, 93.e1-93.e4.	1.3	4
89	Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. New England Journal of Medicine, 2016, 374, 1311-1320.	27.0	546
90	Timing of delivery and pregnancy outcomes in women withÂgestationalÂdiabetes. American Journal of Obstetrics and Gynecology, 2016, 215, 243.e1-243.e7.	1.3	18

#	Article	IF	CITATIONS
91	Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. American Journal of Obstetrics and Gynecology, 2016, 214, 720.e1-720.e17.	1.3	202
92	Preterm neonatal morbidity and mortality by gestational age: aÂcontemporary cohort. American Journal of Obstetrics and Gynecology, 2016, 215, 103.e1-103.e14.	1.3	333
93	Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats. Xenobiotica, 2016, 46, 169-174.	1.1	6
94	Racial and Ethnic Disparities in Maternal Morbidity and Obstetric Care. Obstetrics and Gynecology, 2015, 125, 1460-1467.	2.4	172
95	Population pharmacokinetics of oseltamivir in nonâ€pregnant and pregnant women. British Journal of Clinical Pharmacology, 2015, 80, 1042-1050.	2.4	22
96	Serious maternal complications after early preterm delivery (24-33 weeks' gestation). American Journal of Obstetrics and Gynecology, 2015, 213, 538.e1-538.e9.	1.3	80
97	Timing of treatment initiation for mild gestational diabetes mellitus and perinatal outcomes. American Journal of Obstetrics and Gynecology, 2015, 213, 560.e1-560.e8.	1.3	22
98	Effect of Magnesium Sulfate Administration for Neuroprotection on Latency in Women with Preterm Premature Rupture of Membranes. American Journal of Perinatology, 2015, 32, 387-392.	1.4	12
99	A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b). American Journal of Obstetrics and Gynecology, 2015, 212, 539.e1-539.e24.	1.3	160
100	Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. BMC Pregnancy and Childbirth, 2015, 15, 59.	2.4	31
101	The Association of Cord Serum Cytokines with Neurodevelopmental Outcomes. American Journal of Perinatology, 2015, 30, 115-122.	1.4	26
102	Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. American Journal of Obstetrics and Gynecology, 2015, 213, 541.e1-541.e7.	1.3	44
103	Relation between Birth Weight and Weight and Height at the Age of 2 in Children Born Preterm. American Journal of Perinatology, 2015, 32, 591-598.	1.4	1
104	Pharmacokinetics of drugs in pregnancy. Seminars in Perinatology, 2015, 39, 512-519.	2.5	233
105	Uterine endoplasmic reticulum stress-unfolded protein response regulation of gestational length is caspase-3 and -7–dependent. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14090-14095.	7.1	28
106	Glyburide vs Insulin and Adverse Pregnancy Outcomes. JAMA Pediatrics, 2015, 169, 974.	6.2	0
107	A Randomized Trial of Intrapartum Fetal ECG ST-Segment Analysis. New England Journal of Medicine, 2015, 373, 632-641.	27.0	135
108	Antenatal Magnesium and Cerebral Palsy in Preterm Infants. Journal of Pediatrics, 2015, 167, 834-839.e3.	1.8	37

#	Article	IF	CITATIONS
109	Nonmedically indicated induction vs expectant treatment in term nulliparous women. American Journal of Obstetrics and Gynecology, 2015, 212, 103.e1-103.e7.	1.3	39
110	Umbilical Cord Serum Interleukin-6, C-Reactive Protein, and Myeloperoxidase Concentrations at Birth and Association with Neonatal Morbidities and Long-Term Neurodevelopmental Outcomes. American Journal of Perinatology, 2014, 31, 717-726.	1.4	30
111	Accuracy of Sonographic Chorionicity Classification in Twin Gestations. Journal of Ultrasound in Medicine, 2014, 33, 2187-2192.	1.7	37
112	Maternal Vitamin D Status and Small-for-Gestational-Age Offspring in Women at High Risk for Preeclampsia. Obstetrics and Gynecology, 2014, 123, 40-48.	2.4	73
113	Frequency of and Factors Associated With Severe Maternal Morbidity. Obstetrics and Gynecology, 2014, 123, 804-810.	2.4	176
114	Stability of hydroxyprogesterone caproate alone and in a compounded pharmaceutical product. American Journal of Health-System Pharmacy, 2014, 71, 1120-1127.	1.0	2
115	Quality assessment of compounded 17-hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2014, 210, 47.e1-47.e7.	1.3	12
116	Pharmacokinetics of Indomethacin in Pregnancy. Clinical Pharmacokinetics, 2014, 53, 545-551.	3.5	20
117	Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2014, 210, 128.e1-128.e6.	1.3	45
118	Oseltamivir for influenza in pregnancy. Seminars in Perinatology, 2014, 38, 503-507.	2.5	13
119	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: Pharmacologic considerations. Seminars in Perinatology, 2014, 38, 516-522.	2.5	19
120	Studying the antiemetic effect of vitamin B6 for morning sickness: Pyridoxine and pyridoxal are prodrugs. Journal of Clinical Pharmacology, 2014, 54, 1429-1433.	2.0	8
121	Can differences in obstetric outcomes be explained by differences in the care provided? The MFMU Network APEX study. American Journal of Obstetrics and Gynecology, 2014, 211, 147.e1-147.e16.	1.3	75
122	Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes. American Journal of Obstetrics and Gynecology, 2014, 211, 412.e1-412.e6.	1.3	3
123	Adherence to criteria for transvaginal ultrasound imaging andÂmeasurement of cervical length. American Journal of Obstetrics and Gynecology, 2013, 209, 365.e1-365.e5.	1.3	36
124	Uterine Contraction Agents and Tocolytics. , 2013, , 307-330.		3
125	A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2013, 74, 126-132.	2.8	42
126	The association of cerebral palsy and death with small-for-gestational-age birthweight in preterm neonates by individualized and population-based percentiles. American Journal of Obstetrics and Gynecology, 2013, 209, 340.e1-340.e5.	1.3	20

#	Article	IF	CITATIONS
127	Comparing the Pharmacokinetics of Doxylamine/Pyridoxine Delayedâ€Release Combination in Nonpregnant Women of Reproductive Age and Women in the First Trimester of Pregnancy. Journal of Clinical Pharmacology, 2013, 53, 334-338.	2.0	7
128	Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2013, 208, 470.e1-470.e5.	1.3	7
129	Advanced lipoprotein measures and recurrent preterm birth. American Journal of Obstetrics and Gynecology, 2013, 209, 342.e1-342.e7.	1.3	8
130	Reply. American Journal of Obstetrics and Gynecology, 2013, 209, 285-286.	1.3	0
131	Reply. American Journal of Obstetrics and Gynecology, 2013, 208, 337-338.	1.3	0
132	Gestational age–specific risks vs benefits of multicourse antenatal corticosteroids for preterm labor. American Journal of Obstetrics and Gynecology, 2013, 209, 330.e1-330.e7.	1.3	20
133	Effect of endogenous steroid hormones on 17-alpha-hydroxyprogesterone caproate metabolism. American Journal of Obstetrics and Gynecology, 2013, 208, 86.e1-86.e6.	1.3	11
134	Risk-adjusted models for adverse obstetric outcomes and variation in risk-adjusted outcomes across hospitals. American Journal of Obstetrics and Gynecology, 2013, 209, 446.e1-446.e30.	1.3	77
135	Relationship Between 1-Hour Glucose Challenge Test Results and Perinatal Outcomes. Obstetrics and Gynecology, 2013, 121, 1241-1247.	2.4	21
136	Population versus Customized Fetal Growth Norms and Adverse Outcomes in an Intrapartum Cohort. American Journal of Perinatology, 2013, 30, 335-342.	1.4	16
137	Customized versus Population Approach for Evaluation of Fetal Overgrowth. American Journal of Perinatology, 2013, 30, 565-572.	1.4	14
138	Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic. American Journal of Perinatology, 2013, 30, 275-282.	1.4	38
139	The Impact of Tobacco Use on Preterm Premature Rupture of the Membranes. American Journal of Perinatology, 2013, 30, 185-190.	1.4	1
140	The Obstetric and Neonatal Implications of a Low Value on the 50-g Glucose Screening Test. American Journal of Perinatology, 2013, 30, 715-722.	1.4	7
141	Hepatobiliary Disposition of 17-OHPC and Taurocholate in Fetal Human Hepatocytes: A Comparison with Adult Human Hepatocytes. Drug Metabolism and Disposition, 2013, 41, 296-304.	3.3	32
142	Change in Mononuclear Leukocyte Responsiveness in Midpregnancy and Subsequent Preterm Birth. Obstetrics and Gynecology, 2013, 121, 805-811.	2.4	21
143	A Pharmacologic Approach to the Use of Clyburide in Pregnancy. Obstetrics and Gynecology, 2013, 121, 1309-1312.	2.4	32
144	Timing of Delivery and Adverse Outcomes in Term Singleton Repeat Cesarean Deliveries. Obstetrics and Gynecology, 2013, 121, 561-569.	2.4	69

#	Article	IF	CITATIONS
145	Activity Restriction Among Women With a Short Cervix. Obstetrics and Gynecology, 2013, 121, 1181-1186.	2.4	56
146	Relationship between Fetal Station and Successful Vaginal Delivery in Nulliparous Women. American Journal of Perinatology, 2012, 29, 723-730.	1.4	8
147	Impact of Smoking during Pregnancy on Functional Coagulation Testing. American Journal of Perinatology, 2012, 29, 225-230.	1.4	2
148	Determinants of Adherence to Delayed-Release Doxylamine and Pyridoxine in Patients With Nausea and Vomiting of Pregnancy. Therapeutic Drug Monitoring, 2012, 34, 569-573.	2.0	5
149	Risk of Uterine Rupture and Placenta Accreta With Prior Uterine Surgery Outside of the Lower Segment. Obstetrics and Gynecology, 2012, 120, 1332-1337.	2.4	92
150	Association of Polymorphisms in Neuroprotection and Oxidative Stress Genes and Neurodevelopmental Outcomes After Preterm Birth. Obstetrics and Gynecology, 2012, 120, 542-550.	2.4	19
151	Cervical pessary use and preterm birth: how little we know. Lancet, The, 2012, 379, 1769-1770.	13.7	7
152	Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology, 2012, 207, 396.e1-396.e8.	1.3	36
153	Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. American Journal of Obstetrics and Gynecology, 2012, 207, 398.e1-398.e8.	1.3	48
154	17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Cynecology, 2012, 207, 390.e1-390.e8.	1.3	127
155	14: Effect of prescription medications on 17-alpha-hydroxyprogesterone caproate (17-OHPC) metabolism. American Journal of Obstetrics and Gynecology, 2012, 206, S9.	1.3	3
156	Timing of delivery and pregnancy outcomes among laboring nulliparous women. American Journal of Obstetrics and Gynecology, 2012, 206, 239.e1-239.e8.	1.3	14
157	Elective repeat cesarean delivery compared with spontaneous trial of labor after a prior cesarean delivery: a propensity score analysis. American Journal of Obstetrics and Gynecology, 2012, 206, 311.e1-311.e9.	1.3	38
158	Fetal male gender and the benefits of treatment of mild gestational diabetes mellitus. American Journal of Obstetrics and Gynecology, 2012, 206, 422.e1-422.e5.	1.3	22
159	Association of Cord Blood Magnesium Concentration and Neonatal Resuscitation. Journal of Pediatrics, 2012, 160, 573-577.e1.	1.8	29
160	Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trials. BMC Pregnancy and Childbirth, 2012, 12, 13.	2.4	14
161	Perinatal Outcomes in Hispanic and Non-Hispanic White Women With Mild Gestational Diabetes. Obstetrics and Gynecology, 2012, 120, 1099-1104.	2.4	13
162	Failed Labor Induction Toward an Objective Diagnosis. Obstetrical and Gynecological Survey, 2011, 66, 265-266.	0.4	1

#	Article	IF	CITATIONS
163	Timing of Elective Repeat Cesarean Delivery at Term and Maternal Perioperative Outcomes. Obstetrics and Gynecology, 2011, 117, 280-286.	2.4	74
164	Failed Labor Induction. Obstetrics and Gynecology, 2011, 117, 267-272.	2.4	79
165	Admixture Mapping to Identify Spontaneous Preterm Birth Susceptibility Loci in African Americans. Obstetrics and Gynecology, 2011, 117, 1078-1084.	2.4	20
166	The Effect of Plurality and Obesity on Betamethasone Concentrations in Women at Risk for Preterm Delivery. Obstetrical and Gynecological Survey, 2011, 66, 1-2.	0.4	2
167	The Relationship Between Maternal Glycemia and Perinatal Outcome. Obstetrics and Gynecology, 2011, 117, 218-224.	2.4	132
168	Effect of Antibiotic Exposure on Nugent Score Among Pregnant Women With and Without Bacterial Vaginosis. Obstetrics and Gynecology, 2011, 117, 844-849.	2.4	10
169	The change in the rate of vaginal birth after caesarean section. Paediatric and Perinatal Epidemiology, 2011, 25, 37-43.	1.7	43
170	50: Effects of endogenous steroids on 17alpha-hydroxyprogesterone caproate (17-OHPC) metabolism. American Journal of Obstetrics and Gynecology, 2011, 204, S29.	1.3	2
171	Metaanalysis and labor inhibition therapy. American Journal of Obstetrics and Gynecology, 2011, 204, 95-96.	1.3	5
172	Placental endothelial nitric oxide synthase in multiple and single dose betamethasone exposed pregnancies. American Journal of Obstetrics and Gynecology, 2011, 204, 545.e11-545.e16.	1.3	3
173	Repeated course antenatal steroids, inflammation gene polymorphisms, and neurodevelopmental outcomes at age 2. American Journal of Obstetrics and Gynecology, 2011, 205, 79.e1-79.e5.	1.3	2
174	Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. American Journal of Obstetrics and Gynecology, 2011, 204, S84-S88.	1.3	68
175	Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. American Journal of Obstetrics and Gynecology, 2011, 205, 40.e1-40.e8.	1.3	40
176	Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2011, 205, 135.e1-135.e9.	1.3	56
177	Fish Consumption, Erythrocyte Fatty Acids, and Preterm Birth. Obstetrics and Gynecology, 2011, 117, 1071-1077.	2.4	44
178	Omega-3 Fatty Acid Supplementation to Prevent Recurrent Preterm Birth. Obstetrics and Gynecology, 2010, 115, 234-242.	2.4	96
179	Prothrombin Gene G20210A Mutation and Obstetric Complications. Obstetrics and Gynecology, 2010, 115, 14-20.	2.4	144
180	Comparison of Transverse and Vertical Skin Incision for Emergency Cesarean Delivery. Obstetrics and Gynecology, 2010, 115, 1134-1140.	2.4	102

#	Article	IF	CITATIONS
181	The Effect of Active and Passive Household Cigarette Smoke Exposure on Pregnant Women With Asthma. Chest, 2010, 137, 601-608.	0.8	38
182	Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for Factor V Leiden. Journal of Reproductive Immunology, 2010, 85, 180-185.	1.9	4
183	The effect of maternal body mass index on neonatal outcome in women receiving a single course of antenatal corticosteroids. American Journal of Obstetrics and Gynecology, 2010, 202, 263.e1-263.e5.	1.3	20
184	Association of fetal inflammation and coagulation pathway gene polymorphisms with neurodevelopmental delay at age 2 years. American Journal of Obstetrics and Gynecology, 2010, 203, 83.e1-83.e10.	1.3	24
185	The effect of plurality and obesity on betamethasone concentrations in women at risk for preterm delivery. American Journal of Obstetrics and Gynecology, 2010, 203, 219.e1-219.e5.	1.3	47
186	Beta adrenergic agonists and neonatal outcome. American Journal of Obstetrics and Gynecology, 2010, 203, e16-e17.	1.3	1
187	Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. American Journal of Obstetrics and Gynecology, 2010, 203, 571.e1-571.e7.	1.3	126
188	Avascular Villi, Increased Syncytial Knots, and Hypervascular Villi Are Associated with Pregnancies Complicated by Factor V Leiden Mutation. Pediatric and Developmental Pathology, 2010, 13, 341-347.	1.0	35
189	Metabolism of 17α-Hydroxyprogesterone Caproate, an Agent for Preventing Preterm Birth, by Fetal Hepatocytes. Drug Metabolism and Disposition, 2010, 38, 723-727.	3.3	21
190	Neonatal Outcomes and Operative Vaginal Delivery Versus Cesarean Delivery. American Journal of Perinatology, 2010, 27, 493-499.	1.4	27
191	The Relationship of Asthma-Specific Quality of Life During Pregnancy to Subsequent Asthma and Perinatal Morbidity. Journal of Asthma, 2010, 47, 46-50.	1.7	28
192	Neonatal Outcomes in Twin Pregnancies Delivered Moderately Preterm, Late Preterm, and Term. American Journal of Perinatology, 2010, 27, 537-542.	1.4	70
193	Maternal Serum Interleukin-6, C-Reactive Protein, and Matrix Metalloproteinase-9 Concentrations as Risk Factors for Preterm Birth <32 Weeks and Adverse Neonatal Outcomes. American Journal of Perinatology, 2010, 27, 631-640.	1.4	139
194	Maternal and Neonatal Outcomes of Repeat Cesarean Delivery in Women with a Prior Classical versus Low Transverse Uterine Incision. American Journal of Perinatology, 2010, 27, 791-796.	1.4	27
195	Mode of Delivery in Women with Antepartum Fetal Death and Prior Cesarean Delivery. American Journal of Perinatology, 2010, 27, 825-830.	1.4	26
196	Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1360-1364.	1.5	57
197	The Frequency and Complication Rates of Hysterectomy Accompanying Cesarean Delivery. Obstetrics and Gynecology, 2009, 114, 224-229.	2.4	239
198	Perioperative Antibiotic Prophylaxis for Nonlaboring Cesarean Delivery. Obstetrics and Gynecology, 2009, 114, 752-756.	2.4	35

#	Article	IF	CITATIONS
199	Maternal Obesity, Uterine Activity, and the Risk of Spontaneous Preterm Birth. Obstetrics and Gynecology, 2009, 113, 48-52.	2.4	53
200	Bone Metabolism in Fetuses of Pregnant Women Exposed to Single and Multiple Courses of Corticosteroids. Obstetrics and Gynecology, 2009, 114, 38-44.	2.4	12
201	Prevention of Preterm Birth in Triplets Using 17 Alpha-Hydroxyprogesterone Caproate. Obstetrics and Gynecology, 2009, 113, 285-292.	2.4	116
202	Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology, 2009, 200, 630.e1-630.e8.	1.3	28
203	The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology, 2009, 201, 392.e1-392.e5.	1.3	39
204	Second-stage labor duration in nulliparous women: relationship to maternal and perinatal outcomes. American Journal of Obstetrics and Gynecology, 2009, 201, 357.e1-357.e7.	1.3	211
205	Can a prediction model for vaginal birth after cesarean also predict the probability of morbidity related to a trial of labor?. American Journal of Obstetrics and Gynecology, 2009, 200, 56.e1-56.e6.	1.3	99
206	Timing of Elective Repeat Cesarean Delivery at Term and Neonatal Outcomes. New England Journal of Medicine, 2009, 360, 111-120.	27.0	749
207	A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy. Obstetrical and Gynecological Survey, 2009, 64, 15-17.	0.4	14
208	Failed Operative Vaginal Delivery. Obstetrics and Gynecology, 2009, 114, 1017-1022.	2.4	46
209	Simultaneous quantitation of 17α-hydroxyprogesterone caproate, 17α-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography–mass spectrometry (HPLC–MS/MS). Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 1174-1180.	2.8	33
210	Human decidual cell Toll-like receptor signaling in response to endotoxin: The effect of progestins. American Journal of Obstetrics and Gynecology, 2008, 198, 119.e1-119.e4.	1.3	13
211	Salivary progesterone and estriol among pregnant women treated with 17-α-hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology, 2008, 199, 506.e1-506.e7.	1.3	25
212	Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery. American Journal of Obstetrics and Gynecology, 2008, 199, 30.e1-30.e5.	1.3	74
213	Maternal and fetal Toll-like receptor 4 genotype and chorionic plate inflammatory lesions. American Journal of Obstetrics and Gynecology, 2008, 199, 400.e1-400.e4.	1.3	22
214	A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy. New England Journal of Medicine, 2008, 359, 895-905.	27.0	664
215	Identification of Enzymes Involved in the Metabolism of 17α-Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth. Drug Metabolism and Disposition, 2008, 36, 1896-1902.	3.3	29
216	Cesarean Delivery for the Second Twin. Obstetrics and Gynecology, 2008, 112, 748-752.	2.4	36

13

#	Article	IF	CITATIONS
217	Previous Preterm Cesarean Delivery and Risk of Subsequent Uterine Rupture. Obstetrics and Gynecology, 2008, 111, 648-653.	2.4	100
218	Bone Metabolism in Pregnant Women Exposed to Single Compared With Multiple Courses of Corticosteroids. Obstetrics and Gynecology, 2008, 111, 1352-1358.	2.4	5
219	Pregnancy Outcomes for Women With Placenta Previa in Relation to the Number of Prior Cesarean Deliveries. Obstetrics and Gynecology, 2007, 110, 1249-1255.	2.4	133
220	Perioperative Morbidity and Mortality Among Human Immunodeficiency Virus–Infected Women Undergoing Cesarean Delivery. Obstetrics and Gynecology, 2007, 110, 385-390.	2.4	45
221	Outcomes of Induction of Labor After One Prior Cesarean. Obstetrics and Gynecology, 2007, 109, 262-269.	2.4	110
222	Fetal Pulse Oximetry and Cesarean Delivery. Obstetrical and Gynecological Survey, 2007, 62, 227-228.	0.4	1
223	Comparison of Maternal and Infant Outcomes From Primary Cesarean Delivery During the Second Compared With First Stage of Labor. Obstetrics and Gynecology, 2007, 109, 917-921.	2.4	179
224	Development of a Nomogram for Prediction of Vaginal Birth After Cesarean Delivery. Obstetrics and Gynecology, 2007, 109, 806-812.	2.4	409
225	Prevention of Preterm Delivery. New England Journal of Medicine, 2007, 357, 477-487.	27.0	413
226	Long-Term Outcomes after Repeat Doses of Antenatal Corticosteroids. New England Journal of Medicine, 2007, 357, 1190-1198.	27.0	287
227	A Trial of 17 Alpha-Hydroxyprogesterone Caproate to Prevent Prematurity in Twins. New England Journal of Medicine, 2007, 357, 454-461.	27.0	354
228	Development and validation of a high-performance liquid chromatography–mass spectrometric assay for the determination of 17α-hydroxyprogesterone caproate (17-OHPC) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 856, 141-147.	2.3	7
229	Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. American Journal of Obstetrics and Gynecology, 2007, 197, 599.e1-599.e7.	1.3	69
230	The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Beneficial Effects of Antenatal Repeated Steroids study: impact of repeated doses of antenatal corticosteroids on placental growth and histologic findings. American Journal of Obstetrics and Gynecology, 2007, 197, 281.e1-281.e8.	1.3	31
231	Fetal Injury Associated With Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 885-890.	2.4	214
232	Blood Transfusion and Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 891-897.	2.4	118
233	Maternal Morbidity Associated With Multiple Repeat Cesarean Deliveries. Obstetrics and Gynecology, 2006, 107, 1226-1232.	2.4	1,385
234	Risk of Uterine Rupture With a Trial of Labor in Women With Multiple and Single Prior Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 12-20.	2.4	191

#	Article	IF	CITATIONS
235	Decision-to-Incision Times and Maternal and Infant Outcomes. Obstetrics and Gynecology, 2006, 108, 6-11.	2.4	192
236	Association of Obesity With Pulmonary and Nonpulmonary Complications of Pregnancy in Asthmatic Women. Obstetrics and Gynecology, 2006, 108, 77-82.	2.4	70
237	Spirometry is related to perinatal outcomes in pregnant women with asthma. American Journal of Obstetrics and Gynecology, 2006, 194, 120-126.	1.3	115
238	Midpregnancy genitourinary tract infection with Chlamydia trachomatis: Association with subsequent preterm delivery in women with bacterial vaginosis and Trichomonas vaginalis. American Journal of Obstetrics and Gynecology, 2006, 194, 493-500.	1.3	61
239	Are women with recurrent spontaneous preterm births different from those without such history?. American Journal of Obstetrics and Gynecology, 2006, 194, 1176-1184.	1.3	53
240	A prospective masked observational study of uterine contraction frequency in twins. American Journal of Obstetrics and Gynecology, 2006, 195, 1564-1570.	1.3	28
241	Single versus weekly courses of antenatal corticosteroids: Evaluation of safety and efficacy. American Journal of Obstetrics and Gynecology, 2006, 195, 633-642.	1.3	271
242	The MFMU Cesarean Registry: Impact of fetal size on trialÂof labor success for patients with previous cesareanÂfor dystocia. American Journal of Obstetrics and Cynecology, 2006, 195, 1127-1131.	1.3	51
243	The MFMU Cesarean Registry: Impact of time of day on cesarean complications. American Journal of Obstetrics and Gynecology, 2006, 195, 1132-1137.	1.3	45
244	The Maternal-Fetal Medicine Units Cesarean Registry: Safety and efficacy of a trial of labor in preterm pregnancy after aÂprior cesarean delivery. American Journal of Obstetrics and Gynecology, 2006, 195, 1119-1126.	1.3	90
245	Trial of Labor or Repeat Cesarean Delivery in Women With Morbid Obesity and Previous Cesarean Delivery. Obstetrics and Gynecology, 2006, 108, 125-133.	2.4	167
246	Antioxidants and the Prevention of Preeclampsia — Unresolved Issues. New England Journal of Medicine, 2006, 354, 1841-1843.	27.0	34
247	Fetal Pulse Oximetry and Cesarean Delivery. New England Journal of Medicine, 2006, 355, 2195-2202.	27.0	143
248	Complications of Anesthesia for Cesarean Delivery. Obstetrics and Gynecology, 2005, 106, 281-287.	2.4	85
249	Spontaneous Resolution of Asymptomatic Chlamydia trachomatis in Pregnancy. Obstetrics and Gynecology, 2005, 105, 557-562.	2.4	30
250	The vaginal inflammatory milieu and the risk of early premature preterm rupture of membranes. American Journal of Obstetrics and Gynecology, 2005, 192, 213-218.	1.3	48
251	Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. American Journal of Obstetrics and Gynecology, 2005, 192, 633-639.	1.3	346
252	The Preterm Prediction study: Association between maternal body mass index and spontaneous and indicated preterm birth. American Journal of Obstetrics and Gynecology, 2005, 192, 882-886.	1.3	273

#	Article	IF	CITATIONS
253	The Maternal-Fetal Medicine Unit cesarean registry: Trial of labor with a twin gestation. American Journal of Obstetrics and Gynecology, 2005, 193, 135-140.	1.3	57
254	Differences in inflammatory cytokine and Toll-like receptor genes and bacterial vaginosis in pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, 1478-1485.	1.3	45
255	Cervical anti-inflammatory cytokine concentrations among first-trimester pregnant smokers. American Journal of Obstetrics and Gynecology, 2005, 193, 1999-2003.	1.3	32
256	The MFMU Cesarean Registry: Factors affecting the success of trial of labor after previous cesarean delivery. American Journal of Obstetrics and Gynecology, 2005, 193, 1016-1023.	1.3	410
257	Progesterone for prevention of recurrent preterm birth: Impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology, 2005, 193, 1127-1131.	1.3	88
258	Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery. American Journal of Obstetrics and Gynecology, 2005, 193, 1181-1186.	1.3	34
259	The MFMU Cesarean Registry: Uterine atony after primary cesarean delivery. American Journal of Obstetrics and Cynecology, 2005, 193, 1056-1060.	1.3	60
260	Adverse effects of tocolytic therapy. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 74-78.	2.3	29
261	Does Progesterone Treatment Influence Risk Factors for Recurrent Preterm Delivery?. Obstetrics and Gynecology, 2005, 106, 557-561.	2.4	33
262	Is there a seasonal variation in the diagnosis of oligohydramnios?. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 17, 173-177.	1.5	2
263	Asthma During Pregnancy. Obstetrics and Gynecology, 2004, 103, 5-12.	2.4	173
264	Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. American Journal of Obstetrics and Gynecology, 2004, 190, 737-744.	1.3	102
265	ls early-pregnancy proteinuria associated with an increased rate of preeclampsia in women with pregestational diabetes mellitus?. American Journal of Obstetrics and Gynecology, 2004, 190, 775-778.	1.3	21
266	The maternal-fetal medicine units cesarean registry: chorioamnionitis at term and its duration—relationship to outcomes. American Journal of Obstetrics and Gynecology, 2004, 191, 211-216.	1.3	232
267	Frequency of uterine contractions in asymptomatic pregnant women with or without a short cervix on transvaginal ultrasound scan. American Journal of Obstetrics and Gynecology, 2004, 191, 1253-1256.	1.3	42
268	The relationship of asthma medication use to perinatal outcomes. Journal of Allergy and Clinical Immunology, 2004, 113, 1040-1045.	2.9	189
269	Maternal and Perinatal Outcomes Associated with a Trial of Labor after Prior Cesarean Delivery. New England Journal of Medicine, 2004, 351, 2581-2589.	27.0	1,166
270	An Evidence-Based Approach to the Evaluation and Treatment of Premature Rupture of Membranes: Part I. Obstetrical and Gynecological Survey, 2004, 59, 669-677.	0.4	40

#	Article	IF	CITATIONS
271	An Evidence-Based Approach to the Evaluation and Treatment of Premature Rupture of Membranes: Part II. Obstetrical and Gynecological Survey, 2004, 59, 678-689.	0.4	14
272	Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy. American Journal of Obstetrics and Gynecology, 2003, 189, 560-567.	1.3	79
273	Elevated vaginal pH and neutrophils are associated strongly with early spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2003, 189, 1150-1154.	1.3	69
274	Interleukin-6 promoter â^'174 polymorphism and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2003, 189, 915-918.	1.3	102
275	What we have learned about preeclampsia. Seminars in Perinatology, 2003, 27, 239-246.	2.5	138
276	Randomized Clinical Trial of Metronidazole Plus Erythromycin to Prevent Spontaneous Preterm Delivery in Fetal Fibronectin–Positive Women. Obstetrics and Gynecology, 2003, 101, 847-855.	2.4	97
277	Tumor necrosis factor–α promoter gene polymorphism -308 and chorioamnionitis. Obstetrics and Gynecology, 2003, 102, 162-166.	2.4	28
278	Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate. New England Journal of Medicine, 2003, 348, 2379-2385.	27.0	1,472
279	Randomized Clinical Trial of Metronidazole Plus Erythromycin to Prevent Spontaneous Preterm Delivery in Fetal Fibronectin–Positive Women. Obstetrics and Gynecology, 2003, 101, 847-855.	2.4	101
280	Frequency of Uterine Contractions and the Risk of Spontaneous Preterm Delivery. New England Journal of Medicine, 2002, 346, 250-255.	27.0	185
281	Pharmacologic Inhibition of Preterm Labor. Clinical Obstetrics and Gynecology, 2002, 45, 99-113.	1.1	29
282	Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. American Journal of Obstetrics and Gynecology, 2002, 186, 66-71.	1.3	303
283	Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. American Journal of Obstetrics and Gynecology, 2002, 186, 422-426.	1.3	192
284	The Preterm Prediction Study: Elevated cervical ferritin levels at 22 to 24 weeks of gestation are associated with spontaneous preterm delivery in asymptomatic women. American Journal of Obstetrics and Gynecology, 2002, 186, 458-463.	1.3	35
285	The Preterm Prediction Study: The value of serum alkaline phosphatase, α-fetoprotein, plasma corticotropin-releasing hormone, and other serum markers for the prediction of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2002, 186, 990-996.	1.3	89
286	The Preterm Prediction Study: Association between cervical interleukin 6 concentration and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2001, 184, 483-488.	1.3	117
287	Antiphospholipid antibodies in women at risk for preeclampsia. American Journal of Obstetrics and Gynecology, 2001, 184, 825-834.	1.3	93
288	The Preterm Prediction Study: Toward a multiple-marker test for spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2001, 185, 643-651.	1.3	158

#	Article	IF	CITATIONS
289	The Preterm Prediction Study: Granulocyte colony-stimulating factor and spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 182, 625-630.	1.3	93
290	The Preterm Prediction Study: Cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. American Journal of Obstetrics and Gynecology, 2000, 182, 631-635.	1.3	47
291	The Preterm Prediction Study: Sequential cervical length and fetal fibronectin testing for the prediction of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 182, 636-643.	1.3	123
292	The Preterm Prediction Study: Association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 183, 662-668.	1.3	173
293	The Preterm Prediction Study: Prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. American Journal of Obstetrics and Gynecology, 2000, 183, 738-745.	1.3	315
294	The Preterm Prediction Study: Quantitative fetal fibronectin values and the prediction of spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 2000, 183, 1480-1483.	1.3	73
295	Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. American Journal of Obstetrics and Gynecology, 2000, 183, 1520-1524.	1.3	170
296	Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. American Journal of Obstetrics and Gynecology, 2000, 182, 364-369.	1.3	187
297	Hypertensive disorders in twin versus singleton gestations. American Journal of Obstetrics and Gynecology, 2000, 182, 938-942.	1.3	454
298	PRETERM PREDICTION STUDY: IS SOCIOECONOMIC STATUS A RISK FACTOR FOR BACTERIAL VAGINOSIS IN BLACK OR IN WHITE WOMEN?. American Journal of Perinatology, 2000, Volume 17, 041-046.	1.4	25
299	Safety of labor epidural anesthesia for women with severe hypertensive disease. American Journal of Obstetrics and Gynecology, 1999, 181, 1096-1101.	1.3	58
300	The Preterm Prediction Study: Effect of gestational age and cause of preterm birth on subsequent obstetric outcome. American Journal of Obstetrics and Gynecology, 1999, 181, 1216-1221.	1.3	401
301	The Preterm Prediction Study: Failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth. American Journal of Obstetrics and Gynecology, 1999, 180, 1151-1154.	1.3	33
302	Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial. American Journal of Obstetrics and Gynecology, 1998, 179, 1193-1199.	1.3	31
303	Predictors of pre-eclampsia in women at high risk. American Journal of Obstetrics and Gynecology, 1998, 179, 946-951.	1.3	125
304	The preterm prediction study: Risk factors for indicated preterm births. American Journal of Obstetrics and Gynecology, 1998, 178, 562-567.	1.3	293
305	The Preterm Prediction Study: Recurrence risk of spontaneous preterm birth. American Journal of Obstetrics and Cynecology, 1998, 178, 1035-1040.	1.3	231
306	The effect of oral terbutaline on maternal glucose metabolism and energy expenditure in pregnancy. American Journal of Obstetrics and Gynecology, 1998, 178, 1041-1047.	1.3	19

#	Article	IF	CITATIONS
307	Risk Factors for Preeclampsia, Abruptio Placentae, and Adverse Neonatal Outcomes among Women with Chronic Hypertension. New England Journal of Medicine, 1998, 339, 667-671.	27.0	472
308	Low-Dose Aspirin to Prevent Preeclampsia in Women at High Risk. New England Journal of Medicine, 1998, 338, 701-705.	27.0	633
309	The Preterm Prediction Study: Association of cesarean delivery with increases in maternal weight and body mass index. American Journal of Obstetrics and Gynecology, 1997, 177, 333-341.	1.3	84
310	The preterm prediction study: Patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. American Journal of Obstetrics and Gynecology, 1997, 177, 8-12.	1.3	85
311	The preterm prediction study: Fetal fibronectin, bacterial vaginosis, and peripartum infection. Obstetrics and Gynecology, 1996, 87, 656-660.	2.4	105
312	Contraction inhibition by β-agonists progressively decreases before labor in the rat myometrium. American Journal of Obstetrics and Gynecology, 1996, 174, 1637-1642.	1.3	5
313	The preterm prediction study: Risk factors in twin gestations. American Journal of Obstetrics and Gynecology, 1996, 175, 1047-1053.	1.3	324
314	Alterations in Ovine Myometrial β-Adrenergic Cascade Do Not Mediate Tachyphylaxis to Ritodrine. Journal of Maternal-Fetal and Neonatal Medicine, 1996, 5, 155-160.	1.5	0
315	Alterations in ovine myometrial ?-adrenergic cascade do not mediate tachyphylaxis to ritodrine. The Journal of Maternal-fetal Medicine, 1996, 5, 155-160.	0.3	3
316	Magnesium Sulfate Is a Poor Inhibitor of Oxytocin-Induced Contractility in Pregnant Sheep. Journal of Maternal-Fetal and Neonatal Medicine, 1995, 4, 139-143.	1.5	3
317	Prevention of Preeclampsia with Low-Dose Aspirin in Healthy, Nulliparous Pregnant Women. New England Journal of Medicine, 1993, 329, 1213-1218.	27.0	538
318	Effect of Nicardipine on Contraction Inhibition, β-Adrenergic Receptor Cascade, and Oxytocin Receptors. Journal of Maternal-Fetal and Neonatal Medicine, 1993, 2, 85-90.	1.5	1
319	A Pharmacokinetic Approach to Preterm Labor Inhibition. Journal of Maternal-Fetal and Neonatal Medicine, 1992, 1, 104-116.	1.5	7
320	Comparison of pulsatile and continuous ritodrine administration: Effects on uterine contractility and l²-adrenergic receptor cascade. American Journal of Obstetrics and Gynecology, 1991, 164, 1005-1011.	1.3	21
321	Pharmacokinetics and pharmacodynamics of ritodrine afterintramuscular administration to pregnant women. American Journal of Obstetrics and Gynecology, 1990, 162, 1215-1219.	1.3	14
322	Pharmacokinetics of ritodrine administered intravenously: Recommendations for changes in the current regimen. American Journal of Obstetrics and Gynecology, 1990, 162, 429-437.	1.3	38
323	Pharmacologic Treatment of Preterm Labor. Clinical Obstetrics and Gynecology, 1988, 31, 635-651.	1.1	41
324	A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor. American Journal of Obstetrics and Gynecology, 1984, 150, 7-14.	1.3	87

		15	0
#	Article	IF	CITATIONS
325	Treatment of Preterm Labour A Review of the Therapeutic Options. Drugs, 1983, 26, 243-261.	10.9	37
326	Pharmacodynamics of ritodrine in pregnant women during preterm labor. American Journal of Obstetrics and Gynecology, 1983, 147, 752-759.	1.3	68
327	Pharmacologic inhibition of preterm labor. American Journal of Obstetrics and Gynecology, 1979, 133, 557-578.	1.3	80
328	Comparison of Cesarean Deliveries in a Multicenter U.S. Cohort Using the 10-Group Classification System. American Journal of Perinatology, 0, , .	1.4	0